GE Healthcare and Novavax in order to develop December 2007, in order to develop innovative vaccine production solutions using GE Healthcare’s manufacturing technologies.. A unique opportunity toologies. – pivotal clinical trial Novel 2009 H1N1 VLP vaccine in MexicoNovavax announced that it has a two-stage clinical study of the virus-like – particle H1N1 influenza vaccine initiated in Mexico in cooperation with Avimex Laboratories and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world.
Virus-like particles mimic the external structure of viruses, however, not live genetic material that causes viral replication and infection VLPs rapidly to rapidly to individual virus strains correspond and produces efficient use of portable cell culture. Technology Novavax VLP – based vaccine candidates are produced significantly faster than egg-based vaccines by using proprietary, portable, recombinant cell culture technology.